Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R in newly diagnosed high-risk Burkitt lymphoma
2013-004394-27Phase 2Active
- Sponsor
- HOVON
- Start
- Mar 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab, cyclophosphamide, vincristine, doxorubicin, etoposide and 4 more in Burkitt lymphoma (BL) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival at 2 years. Started Mar 2014; status: active.
02
Drugs
rituximabcyclophosphamidevincristinedoxorubicinetoposide
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2013-004394-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004394-27.